Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Hammer

Showing results (681-690 of 758) with videos related to

Pageof 76
Sort By:
Journal of Clinical Microbiology|September 1, 1996
Evaluation of an infectivity standard for real-time quality control of human immunodeficiency virus type 1 quantitative micrococulture assays. Participating Laboratories of The AIDS Clinical Trials GroupW A Scott, D Brambilla, E Siwak, et al.
The American Journal of Pathology|May 14, 2013
Positioning ganglioside D3 as an immunotherapeutic target in lymphangioleiomyomatosisEmily R Gilbert, Jonathan M Eby, Adam M Hammer, et al.
Antiviral Therapy|May 1, 2001
Meta-analysis of five randomized controlled trials comparing continuation of zidovudine versus switching to didanosine in HIV-infected individualsJ M Raboud, J S Montaner, S Rae, et al.
Annals of Internal Medicine|December 4, 2001
Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320L M Demeter, M D Hughes, R W Coombs, et al.
Topics in HIV Medicine : a Publication of the International AIDS Society, USA|July 24, 2003
Questions to and answers from the International AIDS Society-USA Resistance Testing Guidelines PanelMartin S Hirsch, Françoise Brun-Vézinet, Bonaventura Clotet, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 16, 2004
Comparison of two indinavir/ritonavir regimens in the treatment of HIV-infected individualsEdward P Acosta, Hulin Wu, Scott M Hammer, et al.
Physiological Reports|March 3, 2019
Exercise tolerance through severe and extreme intensity domainsAndrew M Alexander, Kaylin D Didier, Shane M Hammer, et al.
The New England Journal of Medicine|October 10, 1996
A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study TeamS M Hammer, D A Katzenstein, M D Hughes, et al.
The Journal of Infectious Diseases|March 14, 1998
Changes in virologic markers as predictors of CD4 cell decline and progression of disease in human immunodeficiency virus type 1-infected adults treated with nucleosides. AIDS Clinical Trials Group Protocol 175 TeamS A Fiscus, M D Hughes, J L Lathey, et al.
Journal of Strength and Conditioning Research|May 29, 2026
Passive Blood Flow Restriction Accelerates Muscle Recovery After Exercise-Induced Muscle Damage in Healthy, Recreationally Active FemalesMason A Howard, Sean M Lubiak, Jeffrey T Schmidt, et al.
Pageof 76

Showing results (681-690 of 758) with videos related to

Sort By:
Pageof 76
Journal of Clinical Microbiology|September 1, 1996
Evaluation of an infectivity standard for real-time quality control of human immunodeficiency virus type 1 quantitative micrococulture assays. Participating Laboratories of The AIDS Clinical Trials GroupW A Scott, D Brambilla, E Siwak, et al.
The American Journal of Pathology|May 14, 2013
Positioning ganglioside D3 as an immunotherapeutic target in lymphangioleiomyomatosisEmily R Gilbert, Jonathan M Eby, Adam M Hammer, et al.
Antiviral Therapy|May 1, 2001
Meta-analysis of five randomized controlled trials comparing continuation of zidovudine versus switching to didanosine in HIV-infected individualsJ M Raboud, J S Montaner, S Rae, et al.
Annals of Internal Medicine|December 4, 2001
Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320L M Demeter, M D Hughes, R W Coombs, et al.
Topics in HIV Medicine : a Publication of the International AIDS Society, USA|July 24, 2003
Questions to and answers from the International AIDS Society-USA Resistance Testing Guidelines PanelMartin S Hirsch, Françoise Brun-Vézinet, Bonaventura Clotet, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 16, 2004
Comparison of two indinavir/ritonavir regimens in the treatment of HIV-infected individualsEdward P Acosta, Hulin Wu, Scott M Hammer, et al.
Physiological Reports|March 3, 2019
Exercise tolerance through severe and extreme intensity domainsAndrew M Alexander, Kaylin D Didier, Shane M Hammer, et al.
The New England Journal of Medicine|October 10, 1996
A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study TeamS M Hammer, D A Katzenstein, M D Hughes, et al.
The Journal of Infectious Diseases|March 14, 1998
Changes in virologic markers as predictors of CD4 cell decline and progression of disease in human immunodeficiency virus type 1-infected adults treated with nucleosides. AIDS Clinical Trials Group Protocol 175 TeamS A Fiscus, M D Hughes, J L Lathey, et al.
Journal of Strength and Conditioning Research|May 29, 2026
Passive Blood Flow Restriction Accelerates Muscle Recovery After Exercise-Induced Muscle Damage in Healthy, Recreationally Active FemalesMason A Howard, Sean M Lubiak, Jeffrey T Schmidt, et al.
Pageof 76